MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 406322 | Name: PIK-124

Description:

WARNING: This product is for research use only, not for human or veterinary use.

PIK-124 is a potent PI3K inhibitor.

Chemical Structure

PIK-124
PIK-124
CAS#711025-68-2

Theoretical Analysis

MedKoo Cat#: 406322

Name: PIK-124

CAS#: 711025-68-2

Chemical Formula: C19H12ClFN2O3S2

Exact Mass: 433.9962

Molecular Weight: 434.89

Elemental Analysis: C, 52.47; H, 2.78; Cl, 8.15; F, 4.37; N, 6.44; O, 11.04; S, 14.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
PIK124; PIK 124; PIK-124.
IUPAC/Chemical Name
(E)-4-(3-chloro-4-fluorobenzyl)-6-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one
InChi Key
KWDKVVZOYYHCRG-FRKPEAEDSA-N
InChi Code
InChI=1S/C19H12ClFN2O3S2/c20-12-5-11(1-3-13(12)21)8-23-14-6-10(2-4-15(14)26-9-17(23)24)7-16-18(25)22-19(27)28-16/h1-7H,8-9H2,(H,22,25,27)/b16-7+
SMILES Code
O=C1N(CC2=CC=C(F)C(Cl)=C2)C3=CC(/C=C(SC(N4)=S)\C4=O)=CC=C3OC1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs
Storage Condition
0 – 4 oC for short term (weeks to 1 month) or -20 oC for long terms (months to years).
Solubility
Soluble in DMSO, not soluble in water.
Shelf Life
>2 years if stored properly.
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
        

Preparing Stock Solutions

The following data is based on the product molecular weight 434.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1. Torbett, Neil E.; Luna-moran, Antonio; Knight, Zachary A.; Houk, Andrew; Moasser, Mark; Weiss, William; Shokat, Kevan M.; Stokoe, David. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochemical Journal (2008), 415(1), 97-110 2. Kim, Tae-Wan; Dipaolo, Gilbert; Kang, Min Suk; Berman, Diego; McIntire, Laura Beth Johnson. Phosphoinositide modulation for the treatment of neurodegenerative diseases. PCT Int. Appl. (2008), WO 2008064244 A2 20080529 3. Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell (Cambridge, MA, United States) (2006), 125(4), 733-747. 4. Fan, Qi-Wen; Knight, Zachary A.; Goldenberg, David D.; Yu, Wei; Mostov, Keith E.; Stokoe, David; Shokat, Kevan M.; Weiss, William A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006), 9(5), 341-349. 5. Barvian, Nicole Chantel; Kolz, Christine Nylund; Para, Kimberly Suzanne; Patt, William Chester; Visnick, Melean. Preparation of benzoxazin-3-ones and derivatives as inhibitors of PI3K kinase for treating inflammations, cardiovascular diseases and cancers. PCT Int. Appl. (2004), WO 2004052373 A1 20040624.